Drug Type Monoclonal antibody |
Synonyms A-110 (Applied Molecular Evolution/Biosynexus), Pagibaximab (INN/USAN) + [3] |
Target |
Mechanism LTA inhibitors(Lipoteichoic acid inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08960 | Pagibaximab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sepsis | Phase 3 | US | 01 Mar 2009 | |
Neonatal Sepsis | Phase 3 | US | 01 Nov 2001 | |
Staphylococcal Infections | Phase 3 | - | - | |
Staphylococcal Infections | Phase 3 | - | - | |
Staphylococcal Infections | Phase 3 | - | - | |
Staphylococcal Infections | Phase 3 | - | - |
Phase 2/3 | 1,579 | Placebo | lijjwgosgz(rmrrbkjned) = fqznrycwgm pcjwxzxgqu (huwpmqafrn, djwzfwbown - fhdbsgcxos) View more | - | 24 Oct 2011 | ||
Phase 2 | 88 | (rfvywsfyrb) = bakrwhlxkh kriyrbvpai (qdtyviftxu ) | Positive | 01 Aug 2011 | |||
Placebo | (rfvywsfyrb) = mesehtfiji kriyrbvpai (qdtyviftxu ) |